These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18178791)

  • 21. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Perfect 24-hr blood pressure control using self-measured blood pressure and ambulatory blood pressure monitoring in chronic kidney disease].
    Kario K
    Nihon Jinzo Gakkai Shi; 2009; 51(4):465-70. PubMed ID: 19601555
    [No Abstract]   [Full Text] [Related]  

  • 24. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
    Griffin KA; Bidani AK
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
    Morihira M; Kikuchi K; Nakagawa N; Fujino T; Hasebe N
    Nihon Jinzo Gakkai Shi; 2009; 51(4):451-5. PubMed ID: 19601552
    [No Abstract]   [Full Text] [Related]  

  • 26. [Principal entity of hypertension version of CKD guide].
    Kimura G
    Nihon Jinzo Gakkai Shi; 2009; 51(4):442-5. PubMed ID: 19601550
    [No Abstract]   [Full Text] [Related]  

  • 27. [Contribution of diuretics to the treatment of hypertension in patients with CKD].
    Ura N; Yamaji I
    Nihon Jinzo Gakkai Shi; 2009; 51(4):446-50. PubMed ID: 19601551
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
    Chrysant SG
    J Hum Hypertens; 2005 Dec; 19(12):923-31. PubMed ID: 16049519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Secondary prevention of stroke with effective antihypertensive treatment].
    Boye Knudsen S; Strandgaard S; Paulson OB
    Ugeskr Laeger; 2013 Apr; 175(15):1024-8. PubMed ID: 23582123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systolic hypertension.
    Nash DT
    Geriatrics; 2006 Dec; 61(12):22-8. PubMed ID: 17184139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical trials on protective efficacy of antihypertensive agents for organ damage due to diabetes mellitus complicated with hypertension].
    Higashiura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():623-7. PubMed ID: 15171446
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure control and prevention of stroke.
    Karthikeyan VJ; Lip GY
    Expert Rev Neurother; 2006 Feb; 6(2):203-12. PubMed ID: 16466300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of blood pressure control in the patient with diabetes.
    Bakris GL
    Am J Med; 2004 Mar; 116 Suppl 5A():30S-38S. PubMed ID: 15019861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Blood pressure lowering therapy for mild hypertensive patients with a history of stroke].
    Ishikawa E; Ibayashi S
    Nihon Rinsho; 2008 Aug; 66(8):1560-5. PubMed ID: 18700558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Organ protection by angiotensin II receptor blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
    [No Abstract]   [Full Text] [Related]  

  • 39. [Management of hypertension in upheaval?].
    Zidek W; Paul M
    Dtsch Med Wochenschr; 2005 Nov; 130(46):2627. PubMed ID: 16281156
    [No Abstract]   [Full Text] [Related]  

  • 40. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.